person · Reporting owner

Cowen Aaron

Disclosed activity across 6 companies

Tapewire entity: 20922
SEC CIK: 0001869640

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Akili, Inc.AKLI · Entity 89130	Former Director and 10% Owner	August 19, 2022	August 23, 2022
Benitec Biopharma Inc.BNTC · Entity 5596	10% owner	December 23, 2025	December 30, 2025
Social Capital Suvretta Holdings Corp. IIDNAB · Entity 125597	10% owner	August 16, 2021	August 16, 2021
Social Capital Suvretta Holdings Corp. IVDNAD · Entity 123913	10% owner	August 16, 2021	August 16, 2021
Veradermics, IncMANE · Entity 1907	See footnotes	August 19, 2026	August 21, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Akili, Inc.

Report date August 19, 2022 · Filed August 23, 2022

Jointly reported with SCS Sponsor I LLC, Mehta Kishan, ChaChaCha DNA I, LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	6,860,000	Reported balance After 2022-08-19 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2022-08-19 · Exercise / conversion · Acquired 6,220,000 · Balance 6,860,000 F1: The Class B ordinary shares, par value $0.0001 per share (each a "Class B ordinary share"), held by the reporting owner, SCS Sponsor I LLC (the "Sponsor"), converted to the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on a one-for-one basis upon the consummation of the business combination between the Issuer and Akili Interactive Labs, Inc. (the "Business Combination"). F2: The Sponsor is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by SC SPAC Holdings LLC, the successor by merger to ChaChaCha DNA I, LLC ("SC SPAC Holdings"). Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Mehta and Cowen and SC SPAC Holdings may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be.
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2022-08-19 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2022-08-19 · Other · Disposed 6,860,000 · Balance 0 F3: Represents the distribution for no consideration by the Sponsor of 6,860,000 shares of Common Stock to its members pro rata in accordance with their respective interests.
Class B ordinary sharesSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2022-08-19 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-08-19 · Exercise / conversion · Disposed 6,220,000 · Balance 0 F4: The Class B ordinary shares converted to Common Stock on a one-for-one basis upon the consummation of the Business Combination. F1: The Class B ordinary shares, par value $0.0001 per share (each a "Class B ordinary share"), held by the reporting owner, SCS Sponsor I LLC (the "Sponsor"), converted to the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on a one-for-one basis upon the consummation of the business combination between the Issuer and Akili Interactive Labs, Inc. (the "Business Combination"). F2: The Sponsor is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by SC SPAC Holdings LLC, the successor by merger to ChaChaCha DNA I, LLC ("SC SPAC Holdings"). Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Mehta and Cowen and SC SPAC Holdings may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be.

Filing footnotes · ownership attribution and instrument terms

F1: The Class B ordinary shares, par value $0.0001 per share (each a "Class B ordinary share"), held by the reporting owner, SCS Sponsor I LLC (the "Sponsor"), converted to the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on a one-for-one basis upon the consummation of the business combination between the Issuer and Akili Interactive Labs, Inc. (the "Business Combination").

F2: The Sponsor is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by SC SPAC Holdings LLC, the successor by merger to ChaChaCha DNA I, LLC ("SC SPAC Holdings"). Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Mehta and Cowen and SC SPAC Holdings may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be.

F3: Represents the distribution for no consideration by the Sponsor of 6,860,000 shares of Common Stock to its members pro rata in accordance with their respective interests.

F4: The Class B ordinary shares converted to Common Stock on a one-for-one basis upon the consummation of the Business Combination.

Benitec Biopharma Inc.

Report date December 23, 2025 · Filed December 30, 2025

Jointly reported with MONTANOVA CAPITAL, LLC, Averill Master Fund, Ltd., Averill Madison Master Fund, Ltd.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common stock, par value $0.0001 per shareSEC Table I · non-derivative	IndirectSee footnotes	9,620,075	Reported balance After 2025-12-23 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2025-12-23 · Purchase · Acquired 42,600 · Balance 9,620,075 F2: Notes are included on Exhibit 99.1. F1: Notes are included on Exhibit 99.1.
Common stock, par value $0.0001 per shareSEC Table I · non-derivative	IndirectSee footnotes	1,834,053	Reported balance After 2025-12-23 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2025-12-23 · Purchase · Acquired 7,400 · Balance 1,834,053 F3: Notes are included on Exhibit 99.1. F1: Notes are included on Exhibit 99.1.
Common stock, par value $0.0001 per shareSEC Table I · non-derivative	IndirectSee footnotes	9,634,395	Reported balance After 2025-12-26 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2025-12-26 · Purchase · Acquired 14,320 · Balance 9,634,395 F4: Notes are included on Exhibit 99.1. F1: Notes are included on Exhibit 99.1.
Common stock, par value $0.0001 per shareSEC Table I · non-derivative	IndirectSee footnotes	1,836,569	Reported balance After 2025-12-26 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2025-12-26 · Purchase · Acquired 2,516 · Balance 1,836,569 F5: Notes are included on Exhibit 99.1. F1: Notes are included on Exhibit 99.1.
Common stock, par value $0.0001 per shareSEC Table I · non-derivative	IndirectSee footnotes	9,700,195	Reported balance After 2025-12-29 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 5 · 2025-12-29 · Purchase · Acquired 65,800 · Balance 9,700,195 F6: Notes are included on Exhibit 99.1. F1: Notes are included on Exhibit 99.1.
Common stock, par value $0.0001 per shareSEC Table I · non-derivative	IndirectSee footnotes	1,848,156	Reported balance After 2025-12-29 transaction · row 6 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 6 · 2025-12-29 · Purchase · Acquired 11,587 · Balance 1,848,156 F7: Notes are included on Exhibit 99.1. F1: Notes are included on Exhibit 99.1.

Filing footnotes · ownership attribution and instrument terms

F1: Notes are included on Exhibit 99.1.

F2: Notes are included on Exhibit 99.1.

F3: Notes are included on Exhibit 99.1.

F4: Notes are included on Exhibit 99.1.

F5: Notes are included on Exhibit 99.1.

F6: Notes are included on Exhibit 99.1.

F7: Notes are included on Exhibit 99.1.

Social Capital Suvretta Holdings Corp. II

Report date August 16, 2021 · Filed August 16, 2021

Jointly reported with SCS Sponsor II LLC, Palihapitiya Chamath, Mehta Kishan, ChaChaCha DNA II, LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class B ordinary sharesSEC Table II · derivative / convertible security	Direct	6,220,000	Reported balance After 2021-08-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-08-16 · Disposition to issuer · Disposed 75,000 · Balance 6,220,000 F1: As described in the issuer's registration statement on Form S-1 (File No. 333-256724) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date. F2: On August 16, 2021, SCS Sponsor II LLC forfeited at no cost 75,000 shares of Class B ordinary shares of the issuer in connection with the election by the underwriters of the issuer's initial public offering to decline to exercise in full their option to purchase additional Class A ordinary shares. F3: The reporting owner, SCS Sponsor II LLC (the "Sponsor"), in whose name the securities reported herein are held, is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by ChaChaCha DNA II, LLC ("ChaChaCha"), which is controlled by Mr. Palihapitiya. Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Palihapitiya, Mehta and Cowen and ChaChaCha may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Each of Mr. Palihapitiya, Mr. Mehta, ChaChaCha and Mr. Cowen disclaims beneficial ownership of the shares held by the Sponsor, except to the extent of such person's pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: As described in the issuer's registration statement on Form S-1 (File No. 333-256724) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date.

F2: On August 16, 2021, SCS Sponsor II LLC forfeited at no cost 75,000 shares of Class B ordinary shares of the issuer in connection with the election by the underwriters of the issuer's initial public offering to decline to exercise in full their option to purchase additional Class A ordinary shares.

F3: The reporting owner, SCS Sponsor II LLC (the "Sponsor"), in whose name the securities reported herein are held, is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by ChaChaCha DNA II, LLC ("ChaChaCha"), which is controlled by Mr. Palihapitiya. Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Palihapitiya, Mehta and Cowen and ChaChaCha may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Each of Mr. Palihapitiya, Mr. Mehta, ChaChaCha and Mr. Cowen disclaims beneficial ownership of the shares held by the Sponsor, except to the extent of such person's pecuniary interest therein.

Social Capital Suvretta Holdings Corp. IV

Report date August 16, 2021 · Filed August 16, 2021

Jointly reported with SCS Sponsor IV LLC, Palihapitiya Chamath, Mehta Kishan, ChaChaCha DNA IV, LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class B ordinary sharesSEC Table II · derivative / convertible security	Direct	6,220,000	Reported balance After 2021-08-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-08-16 · Disposition to issuer · Disposed 75,000 · Balance 6,220,000 F1: As described in the issuer's registration statement on Form S-1 (File No. 333-256727) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date. F2: On August 16, 2021, SCS Sponsor IV LLC forfeited at no cost 75,000 shares of Class B common stock of the issuer in connection with the election by the underwriters of the issuer's initial public offering to decline to exercise in full their option to purchase additional Class A ordinary shares. F3: The reporting owner, SCS Sponsor IV LLC (the "Sponsor"), in whose name the securities reported herein are held, is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by ChaChaCha DNA IV, LLC ("ChaChaCha"), which is controlled by Mr. Palihapitiya. Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Palihapitiya, Mehta and Cowen and ChaChaCha may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Each of Mr. Palihapitiya, Mr. Mehta, ChaChaCha and Mr. Cowen disclaims beneficial ownership of the shares held by the Sponsor, except to the extent of such person's pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: As described in the issuer's registration statement on Form S-1 (File No. 333-256727) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date.

F2: On August 16, 2021, SCS Sponsor IV LLC forfeited at no cost 75,000 shares of Class B common stock of the issuer in connection with the election by the underwriters of the issuer's initial public offering to decline to exercise in full their option to purchase additional Class A ordinary shares.

F3: The reporting owner, SCS Sponsor IV LLC (the "Sponsor"), in whose name the securities reported herein are held, is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by ChaChaCha DNA IV, LLC ("ChaChaCha"), which is controlled by Mr. Palihapitiya. Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Palihapitiya, Mehta and Cowen and ChaChaCha may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Each of Mr. Palihapitiya, Mr. Mehta, ChaChaCha and Mr. Cowen disclaims beneficial ownership of the shares held by the Sponsor, except to the extent of such person's pecuniary interest therein.

Veradermics, Inc

Report date August 19, 2026 · Filed August 21, 2026

Jointly reported with MONTANOVA CAPITAL, LLC, Averill Master Fund, Ltd., Averill Madison Master Fund, Ltd.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common stock, par value $0.00001 per shareSEC Table I · non-derivative	IndirectSee footnotes	2,957,937	Reported balance After 2026-08-19 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2026-08-19 · Sale · Disposed 690,601 · Balance 2,957,937 F2: Notes are included on Exhibit 99.1. F1: Notes are included on Exhibit 99.1.
Common stock, par value $0.00001 per shareSEC Table I · non-derivative	IndirectSee footnotes	461,033	Reported balance After 2026-08-19 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2026-08-19 · Sale · Disposed 59,399 · Balance 461,033 F3: Notes are included on Exhibit 99.1. F1: Notes are included on Exhibit 99.1.
Common stock, par value $0.00001 per shareSEC Table I · non-derivative	IndirectSee footnotes	3,106,937	Reported balance After 2026-08-20 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2026-08-20 · Other · Acquired 149,000 · Balance 3,106,937 F4: Notes are included on Exhibit 99.1. F6: Notes are included on Exhibit 99.1. F1: Notes are included on Exhibit 99.1.
Common stock, par value $0.00001 per shareSEC Table I · non-derivative	IndirectSee footnotes	612,033	Reported balance After 2026-08-20 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2026-08-20 · Other · Acquired 151,000 · Balance 612,033 F5: Notes are included on Exhibit 99.1. F6: Notes are included on Exhibit 99.1. F1: Notes are included on Exhibit 99.1.
Pre-Funded WarrantsSEC Table II · derivative / convertible security	IndirectSee footnotes	0	Reported balance After 2026-08-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-08-20 · Other · Disposed 149,000 · Balance 0 F6: Notes are included on Exhibit 99.1. F4: Notes are included on Exhibit 99.1. F7: Notes are included on Exhibit 99.1. F8: Notes are included on Exhibit 99.1. F1: Notes are included on Exhibit 99.1.
Pre-Funded WarrantsSEC Table II · derivative / convertible security	IndirectSee footnotes	0	Reported balance After 2026-08-20 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-08-20 · Other · Disposed 151,000 · Balance 0 F6: Notes are included on Exhibit 99.1. F5: Notes are included on Exhibit 99.1. F7: Notes are included on Exhibit 99.1. F8: Notes are included on Exhibit 99.1. F1: Notes are included on Exhibit 99.1.

Filing footnotes · ownership attribution and instrument terms

F1: Notes are included on Exhibit 99.1.

F2: Notes are included on Exhibit 99.1.

F3: Notes are included on Exhibit 99.1.

F4: Notes are included on Exhibit 99.1.

F5: Notes are included on Exhibit 99.1.

F6: Notes are included on Exhibit 99.1.

F7: Notes are included on Exhibit 99.1.

F8: Notes are included on Exhibit 99.1.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

PROKIDNEY CORP.

Report date July 11, 2025 · Filed July 11, 2025

Section 16 reporting ended · disclosed 2025-07-11. Current position is not established by this disclosure.

No balance rows disclosed in this filing.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
December 23, 2024 Filed Dec 26, 2024 21:28 UTC	Benitec Biopharma Inc. BNTC · Entity 5596	PurchaseCommon stock, par value $0.0001 per share	24,360	$10.98	$267,472.80	Disclosure SEC source: 0000899140-24-001385 · form4.xml · nonDerivative · entry 1 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 7,981,725 F2 · shares: Notes are included on Exhibit 99.1. F2 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F2 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document
December 03, 2024 Filed Dec 5, 2024 21:36 UTC	Benitec Biopharma Inc. BNTC · Entity 5596	PurchaseCommon stock, par value $0.0001 per share	4,810	$9.60	$46,176.00	Disclosure SEC source: 0000899140-24-001318 · form4.xml · nonDerivative · entry 2 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 955,124 F3 · shares: Notes are included on Exhibit 99.1. F3 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F3 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document
December 03, 2024 Filed Dec 5, 2024 21:36 UTC	Benitec Biopharma Inc. BNTC · Entity 5596	PurchaseCommon stock, par value $0.0001 per share	37,190	$9.60	$357,024.00	Disclosure SEC source: 0000899140-24-001318 · form4.xml · nonDerivative · entry 1 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 7,957,365 F2 · shares: Notes are included on Exhibit 99.1. F2 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F2 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document
November 20, 2024 Filed Nov 21, 2024 21:24 UTC	Benitec Biopharma Inc. BNTC · Entity 5596	PurchaseCommon stock, par value $0.0001 per share	3,076	$10.22	$31,436.72	Disclosure SEC source: 0000899140-24-001299 · form4.xml · nonDerivative · entry 4 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 950,314 F5 · shares: Notes are included on Exhibit 99.1. F5 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F5 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document
November 20, 2024 Filed Nov 21, 2024 21:24 UTC	Benitec Biopharma Inc. BNTC · Entity 5596	PurchaseCommon stock, par value $0.0001 per share	24,360	$10.22	$248,959.20	Disclosure SEC source: 0000899140-24-001299 · form4.xml · nonDerivative · entry 3 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 7,920,175 F4 · shares: Notes are included on Exhibit 99.1. F4 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F4 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document
November 19, 2024 Filed Nov 21, 2024 21:24 UTC	Benitec Biopharma Inc. BNTC · Entity 5596	PurchaseCommon stock, par value $0.0001 per share	1,570	$9.73	$15,276.10	Disclosure SEC source: 0000899140-24-001299 · form4.xml · nonDerivative · entry 2 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 947,238 F3 · shares: Notes are included on Exhibit 99.1. F3 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F3 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document
November 19, 2024 Filed Nov 21, 2024 21:24 UTC	Benitec Biopharma Inc. BNTC · Entity 5596	PurchaseCommon stock, par value $0.0001 per share	12,430	$9.73	$120,943.90	Disclosure SEC source: 0000899140-24-001299 · form4.xml · nonDerivative · entry 1 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 7,895,815 F2 · shares: Notes are included on Exhibit 99.1. F2 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F2 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document
September 26, 2024 Filed Sep 30, 2024 21:17 UTC	Benitec Biopharma Inc. BNTC · Entity 5596	OtherPre-Funded Warrants · Derivative	148,210	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899140-24-001042 · form4.xml · derivative · entry 10 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Cowen Aaron · CIK 0001869640 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 428,137 Underlying: Common Stock · 576,347 shares Expires not disclosed F7 · derivative.expiration_date: Notes are included on Exhibit 99.1. F6 · derivative.underlying_shares: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F6 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document
September 26, 2024 Filed Sep 30, 2024 21:17 UTC	Benitec Biopharma Inc. BNTC · Entity 5596	OtherCommon Warrants · Derivative	576,347	$0.00 Strike: $3.86	$0.00	Disclosure SEC source: 0000899140-24-001042 · form4.xml · derivative · entry 9 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Cowen Aaron · CIK 0001869640 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 576,347 shares Expires 2028-08-11 F5 · derivative.underlying_shares: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F5 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document
September 26, 2024 Filed Sep 30, 2024 21:17 UTC	Benitec Biopharma Inc. BNTC · Entity 5596	OtherPre-Funded Warrants · Derivative	1,219,970	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899140-24-001042 · form4.xml · derivative · entry 8 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Cowen Aaron · CIK 0001869640 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 3,385,030 Underlying: Common Stock · 4,605,000 shares Expires not disclosed F7 · derivative.expiration_date: Notes are included on Exhibit 99.1. F4 · derivative.underlying_shares: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F4 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document
September 26, 2024 Filed Sep 30, 2024 21:17 UTC	Benitec Biopharma Inc. BNTC · Entity 5596	OtherCommon Warrants · Derivative	4,605,000	$0.00 Strike: $3.86	$0.00	Disclosure SEC source: 0000899140-24-001042 · form4.xml · derivative · entry 7 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Cowen Aaron · CIK 0001869640 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 4,605,000 shares Expires 2028-08-11 F3 · derivative.underlying_shares: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F3 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document
September 26, 2024 Filed Sep 30, 2024 21:17 UTC	Benitec Biopharma Inc. BNTC · Entity 5596	OtherSeries 2 Common Warrants · Derivative	10,000,000	$0.00 Strike: $1.93	$0.00	Disclosure SEC source: 0000899140-24-001042 · form4.xml · derivative · entry 6 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Cowen Aaron · CIK 0001869640 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 588,236 shares Expires 2027-12-09 F2 · derivative.underlying_shares: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F2 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document
September 26, 2024 Filed Sep 30, 2024 21:17 UTC	Benitec Biopharma Inc. BNTC · Entity 5596	OtherCommon stock, par value $0.0001 per share	148,210	$0.00	$14.82	Disclosure SEC source: 0000899140-24-001042 · form4.xml · nonDerivative · entry 5 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Cowen Aaron · CIK 0001869640 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 945,668 F6 · shares: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F6 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document
September 26, 2024 Filed Sep 30, 2024 21:17 UTC	Benitec Biopharma Inc. BNTC · Entity 5596	OtherCommon stock, par value $0.0001 per share	576,347	$3.86	$2,224,699.42	Disclosure SEC source: 0000899140-24-001042 · form4.xml · nonDerivative · entry 4 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Cowen Aaron · CIK 0001869640 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 797,458 F5 · shares: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F5 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document
September 26, 2024 Filed Sep 30, 2024 21:17 UTC	Benitec Biopharma Inc. BNTC · Entity 5596	OtherCommon stock, par value $0.0001 per share	1,219,970	$0.00	$122.00	Disclosure SEC source: 0000899140-24-001042 · form4.xml · nonDerivative · entry 3 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Cowen Aaron · CIK 0001869640 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 7,883,385 F4 · shares: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F4 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document
September 26, 2024 Filed Sep 30, 2024 21:17 UTC	Benitec Biopharma Inc. BNTC · Entity 5596	OtherCommon stock, par value $0.0001 per share	4,605,000	$3.86	$17,775,300.00	Disclosure SEC source: 0000899140-24-001042 · form4.xml · nonDerivative · entry 2 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Cowen Aaron · CIK 0001869640 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 6,663,415 F3 · shares: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F3 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document
September 26, 2024 Filed Sep 30, 2024 21:17 UTC	Benitec Biopharma Inc. BNTC · Entity 5596	OtherCommon stock, par value $0.0001 per share	588,236	$1.93	$1,135,236.66	Disclosure SEC source: 0000899140-24-001042 · form4.xml · nonDerivative · entry 1 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Cowen Aaron · CIK 0001869640 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 2,058,415 F2 · shares: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F2 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document
March 31, 2023 Filed Apr 4, 2023 20:46 UTC	PROKIDNEY CORP. PROK · Entity 5181	OtherClass A ordinary shares	857,500	$0.00	$0.00	Disclosure SEC source: 0000899140-23-000514 · form4.xml · nonDerivative · entry 2 Cowen Aaron · CIK 0001869640 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 4,050,675 F3 · kind: See Exhibit 99.1 F3 · shares: See Exhibit 99.1 F3 · price: See Exhibit 99.1 F3 · ownership.nature: See Exhibit 99.1 F4 · ownership.nature: See Exhibit 99.1 Read SEC document
March 31, 2023 Filed Apr 4, 2023 20:46 UTC	PROKIDNEY CORP. PROK · Entity 5181	OtherClass A ordinary shares	3,087,000	$0.00	$0.00	Disclosure SEC source: 0000899140-23-000514 · form4.xml · nonDerivative · entry 1 Cowen Aaron · CIK 0001869640 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 3,193,175 F1 · kind: See Exhibit 99.1 F1 · shares: See Exhibit 99.1 F1 · price: See Exhibit 99.1 F2 · balance_after: See Exhibit 99.1 F2 · ownership.nature: See Exhibit 99.1 F4 · ownership.nature: See Exhibit 99.1 Read SEC document
September 06, 2022 Filed Sep 8, 2022 20:48 UTC	PROKIDNEY CORP. PROK · Entity 5181	PurchaseClass A Ordinary Shares	7,007	$6.99	$48,978.93	Disclosure SEC source: 0001567619-22-017178 · doc1.xml · nonDerivative · entry 1 Cowen Aaron · CIK 0001869640 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 6,280,175 F1 · shares: Notes are included on Exhibit 99.1. F2 · balance_after: Notes are included on Exhibit 99.1. F3 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document
August 31, 2022 Filed Sep 1, 2022 16:46 UTC	PROKIDNEY CORP. PROK · Entity 5181	PurchaseClass A Ordinary Shares	2,100	$8.94	$18,774.00	Disclosure SEC source: 0001567619-22-016896 · doc1.xml · nonDerivative · entry 3 Cowen Aaron · CIK 0001869640 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 6,273,168 F1 · shares: See Exhibit 99.1 F4 · balance_after: See Exhibit 99.1 F5 · ownership.nature: See Exhibit 99.1 Read SEC document
August 31, 2022 Filed Sep 1, 2022 16:46 UTC	PROKIDNEY CORP. PROK · Entity 5181	PurchaseClass A Ordinary Shares	1,062	$8.93	$9,483.66	Disclosure SEC source: 0001567619-22-016896 · doc1.xml · nonDerivative · entry 2 Cowen Aaron · CIK 0001869640 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 6,271,068 F1 · shares: See Exhibit 99.1 F3 · balance_after: See Exhibit 99.1 F5 · ownership.nature: See Exhibit 99.1 Read SEC document
August 30, 2022 Filed Sep 1, 2022 16:46 UTC	PROKIDNEY CORP. PROK · Entity 5181	PurchaseClass A Ordinary Shares	706	$7.49	$5,287.94	Disclosure SEC source: 0001567619-22-016896 · doc1.xml · nonDerivative · entry 1 Cowen Aaron · CIK 0001869640 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 6,270,006 F1 · shares: See Exhibit 99.1 F2 · balance_after: See Exhibit 99.1 F5 · ownership.nature: See Exhibit 99.1 Read SEC document
August 19, 2022 Filed Aug 23, 2022 17:28 UTC	Akili, Inc. AKLI · Entity 89130	Exercise / conversionClass B ordinary shares · Derivative	6,220,000	$0.00	$0.00	Disclosure SEC source: 0001209191-22-047241 · doc4.xml · derivative · entry 3 SCS Sponsor I LLC · CIK 0001850369 · Former Director and 10% Owner Mehta Kishan · CIK 0001850520 · Former Director and 10% Owner Cowen Aaron · CIK 0001869640 · Former Director and 10% Owner ChaChaCha DNA I, LLC · CIK 0001869714 · Former Director and 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A ordinary shares · 6,220,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The Class B ordinary shares converted to Common Stock on a one-for-one basis upon the consummation of the Business Combination. F4 · derivative.exercise_date: The Class B ordinary shares converted to Common Stock on a one-for-one basis upon the consummation of the Business Combination. F4 · derivative.expiration_date: The Class B ordinary shares converted to Common Stock on a one-for-one basis upon the consummation of the Business Combination. F1 · ownership.direct: The Class B ordinary shares, par value $0.0001 per share (each a "Class B ordinary share"), held by the reporting owner, SCS Sponsor I LLC (the "Sponsor"), converted to the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on a one-for-one basis upon the consummation of the business combination between the Issuer and Akili Interactive Labs, Inc. (the "Business Combination"). F2 · ownership.direct: The Sponsor is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by SC SPAC Holdings LLC, the successor by merger to ChaChaCha DNA I, LLC ("SC SPAC Holdings"). Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Mehta and Cowen and SC SPAC Holdings may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Read SEC document
August 19, 2022 Filed Aug 23, 2022 17:28 UTC	Akili, Inc. AKLI · Entity 89130	OtherCommon Stock	6,860,000	$0.00	$0.00	Disclosure SEC source: 0001209191-22-047241 · doc4.xml · nonDerivative · entry 2 SCS Sponsor I LLC · CIK 0001850369 · Former Director and 10% Owner Mehta Kishan · CIK 0001850520 · Former Director and 10% Owner Cowen Aaron · CIK 0001869640 · Former Director and 10% Owner ChaChaCha DNA I, LLC · CIK 0001869714 · Former Director and 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · ownership.direct: Represents the distribution for no consideration by the Sponsor of 6,860,000 shares of Common Stock to its members pro rata in accordance with their respective interests. Read SEC document
August 19, 2022 Filed Aug 23, 2022 17:28 UTC	Akili, Inc. AKLI · Entity 89130	Exercise / conversionCommon Stock	6,220,000	$0.00	$0.00	Disclosure SEC source: 0001209191-22-047241 · doc4.xml · nonDerivative · entry 1 SCS Sponsor I LLC · CIK 0001850369 · Former Director and 10% Owner Mehta Kishan · CIK 0001850520 · Former Director and 10% Owner Cowen Aaron · CIK 0001869640 · Former Director and 10% Owner ChaChaCha DNA I, LLC · CIK 0001869714 · Former Director and 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,860,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: The Class B ordinary shares, par value $0.0001 per share (each a "Class B ordinary share"), held by the reporting owner, SCS Sponsor I LLC (the "Sponsor"), converted to the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on a one-for-one basis upon the consummation of the business combination between the Issuer and Akili Interactive Labs, Inc. (the "Business Combination"). F2 · ownership.direct: The Sponsor is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by SC SPAC Holdings LLC, the successor by merger to ChaChaCha DNA I, LLC ("SC SPAC Holdings"). Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Mehta and Cowen and SC SPAC Holdings may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Read SEC document
July 11, 2022 Filed Jul 13, 2022 16:25 UTC	PROKIDNEY CORP. PROK · Entity 5181	Exercise / conversionClass B ordinary shares · Derivative	6,220,000	$0.00	$0.00	Disclosure SEC source: 0001209191-22-042045 · doc4.xml · derivative · entry 3 SCS Sponsor III LLC · CIK 0001850379 · Former Director and 10% Owner Mehta Kishan · CIK 0001850520 · Former Director and 10% Owner Cowen Aaron · CIK 0001869640 · Former Director and 10% Owner ChaChaCha DNA III, LLC · CIK 0001869713 · Former Director and 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A ordinary shares · 6,220,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The Class B ordinary shares were automatically convertible into Class A ordinary shares at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustments, and had no expiration date. F4 · derivative.exercise_date: The Class B ordinary shares were automatically convertible into Class A ordinary shares at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustments, and had no expiration date. F4 · derivative.expiration_date: The Class B ordinary shares were automatically convertible into Class A ordinary shares at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustments, and had no expiration date. F1 · ownership.direct: The Class B ordinary shares held by the reporting owner, SCS Sponsor III LLC (the "Sponsor"), converted to Class A ordinary shares on a one-for-one basis upon the consummation of the business combination between the issuer and ProKidney LP. F2 · ownership.direct: The Sponsor is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by SC SPAC Holdings LLC, the successor by merger to ChaChaCha DNA III, LLC ("SC SPAC Holdings"). Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Mehta and Cowen and SC SPAC Holdings may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Read SEC document
July 11, 2022 Filed Jul 13, 2022 16:25 UTC	PROKIDNEY CORP. PROK · Entity 5181	OtherClass A ordinary shares	6,860,000	$0.00	$0.00	Disclosure SEC source: 0001209191-22-042045 · doc4.xml · nonDerivative · entry 2 SCS Sponsor III LLC · CIK 0001850379 · Former Director and 10% Owner Mehta Kishan · CIK 0001850520 · Former Director and 10% Owner Cowen Aaron · CIK 0001869640 · Former Director and 10% Owner ChaChaCha DNA III, LLC · CIK 0001869713 · Former Director and 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · ownership.direct: Represents the distribution for no consideration by the Sponsor of 6,860,000 Class A ordinary shares to its members pro rata in accordance with their respective interests. Read SEC document
July 11, 2022 Filed Jul 13, 2022 16:25 UTC	PROKIDNEY CORP. PROK · Entity 5181	Exercise / conversionClass A ordinary shares	6,220,000	$0.00	$0.00	Disclosure SEC source: 0001209191-22-042045 · doc4.xml · nonDerivative · entry 1 SCS Sponsor III LLC · CIK 0001850379 · Former Director and 10% Owner Mehta Kishan · CIK 0001850520 · Former Director and 10% Owner Cowen Aaron · CIK 0001869640 · Former Director and 10% Owner ChaChaCha DNA III, LLC · CIK 0001869713 · Former Director and 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,860,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: The Class B ordinary shares held by the reporting owner, SCS Sponsor III LLC (the "Sponsor"), converted to Class A ordinary shares on a one-for-one basis upon the consummation of the business combination between the issuer and ProKidney LP. F2 · ownership.direct: The Sponsor is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by SC SPAC Holdings LLC, the successor by merger to ChaChaCha DNA III, LLC ("SC SPAC Holdings"). Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Mehta and Cowen and SC SPAC Holdings may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Read SEC document
August 16, 2021 Filed Aug 16, 2021 18:28 UTC	Social Capital Suvretta Holdings Corp. II DNAB · Entity 125597	Disposition to issuerClass B ordinary shares · Derivative	75,000	$0.00	$0.00	Disclosure SEC source: 0001209191-21-051677 · doc4.xml · derivative · entry 1 SCS Sponsor II LLC · CIK 0001850373 · Director · 10% owner Palihapitiya Chamath · CIK 0001715450 · Director · Chief Executive Officer · 10% owner Mehta Kishan · CIK 0001850520 · Director · President · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner ChaChaCha DNA II, LLC · CIK 0001869716 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,220,000 Underlying: Class A ordinary shares · 75,000 shares Expires not disclosed F1 · derivative.exercise_price: As described in the issuer's registration statement on Form S-1 (File No. 333-256724) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date. F2 · kind: On August 16, 2021, SCS Sponsor II LLC forfeited at no cost 75,000 shares of Class B ordinary shares of the issuer in connection with the election by the underwriters of the issuer's initial public offering to decline to exercise in full their option to purchase additional Class A ordinary shares. F1 · derivative.exercise_date: As described in the issuer's registration statement on Form S-1 (File No. 333-256724) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date. F1 · derivative.expiration_date: As described in the issuer's registration statement on Form S-1 (File No. 333-256724) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date. F3 · ownership.direct: The reporting owner, SCS Sponsor II LLC (the "Sponsor"), in whose name the securities reported herein are held, is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by ChaChaCha DNA II, LLC ("ChaChaCha"), which is controlled by Mr. Palihapitiya. Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Palihapitiya, Mehta and Cowen and ChaChaCha may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Each of Mr. Palihapitiya, Mr. Mehta, ChaChaCha and Mr. Cowen disclaims beneficial ownership of the shares held by the Sponsor, except to the extent of such person's pecuniary interest therein. Read SEC document
August 16, 2021 Filed Aug 16, 2021 18:31 UTC	PROKIDNEY CORP. DNAC · Entity 5181	Disposition to issuerClass B ordinary shares · Derivative	75,000	$0.00	$0.00	Disclosure SEC source: 0001209191-21-051681 · doc4.xml · derivative · entry 1 SCS Sponsor III LLC · CIK 0001850379 · Director · 10% owner Palihapitiya Chamath · CIK 0001715450 · Director · Chief Executive Officer · 10% owner Mehta Kishan · CIK 0001850520 · Director · President · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner ChaChaCha DNA III, LLC · CIK 0001869713 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,220,000 Underlying: Class A ordinary shares · 75,000 shares Expires not disclosed F1 · derivative.exercise_price: As described in the issuer's registration statement on Form S-1 (File No. 333-256725) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date. F2 · kind: On August 16, 2021, SCS Sponsor III LLC forfeited at no cost 75,000 shares of Class B common stock of the issuer in connection with the election by the underwriters of the issuer's initial public offering to decline to exercise in full their option to purchase additional Class A ordinary shares. F1 · derivative.exercise_date: As described in the issuer's registration statement on Form S-1 (File No. 333-256725) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date. F1 · derivative.expiration_date: As described in the issuer's registration statement on Form S-1 (File No. 333-256725) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date. F3 · ownership.direct: The reporting owner, SCS Sponsor III LLC (the "Sponsor"), in whose name the securities reported herein are held, is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by ChaChaCha DNA III, LLC ("ChaChaCha"), which is controlled by Mr. Palihapitiya. Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Palihapitiya, Mehta and Cowen and ChaChaCha may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Each of Mr. Palihapitiya, Mr. Mehta, ChaChaCha and Mr. Cowen disclaims beneficial ownership of the shares held by the Sponsor, except to the extent of such person's pecuniary interest therein. Read SEC document
August 16, 2021 Filed Aug 16, 2021 18:34 UTC	Social Capital Suvretta Holdings Corp. IV DNAD · Entity 123913	Disposition to issuerClass B ordinary shares · Derivative	75,000	$0.00	$0.00	Disclosure SEC source: 0001209191-21-051683 · doc4.xml · derivative · entry 1 SCS Sponsor IV LLC · CIK 0001850376 · Director · 10% owner Palihapitiya Chamath · CIK 0001715450 · Director · Chief Executive Officer · 10% owner Mehta Kishan · CIK 0001850520 · Director · President · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner ChaChaCha DNA IV, LLC · CIK 0001869773 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,220,000 Underlying: Class A ordinary shares · 75,000 shares Expires not disclosed F1 · derivative.exercise_price: As described in the issuer's registration statement on Form S-1 (File No. 333-256727) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date. F2 · kind: On August 16, 2021, SCS Sponsor IV LLC forfeited at no cost 75,000 shares of Class B common stock of the issuer in connection with the election by the underwriters of the issuer's initial public offering to decline to exercise in full their option to purchase additional Class A ordinary shares. F1 · derivative.exercise_date: As described in the issuer's registration statement on Form S-1 (File No. 333-256727) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date. F1 · derivative.expiration_date: As described in the issuer's registration statement on Form S-1 (File No. 333-256727) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date. F3 · ownership.direct: The reporting owner, SCS Sponsor IV LLC (the "Sponsor"), in whose name the securities reported herein are held, is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by ChaChaCha DNA IV, LLC ("ChaChaCha"), which is controlled by Mr. Palihapitiya. Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Palihapitiya, Mehta and Cowen and ChaChaCha may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Each of Mr. Palihapitiya, Mr. Mehta, ChaChaCha and Mr. Cowen disclaims beneficial ownership of the shares held by the Sponsor, except to the extent of such person's pecuniary interest therein. Read SEC document
August 16, 2021 Filed Aug 16, 2021 18:25 UTC	Akili, Inc. DNAA · Entity 89130	Disposition to issuerClass B ordinary shares · Derivative	75,000	$0.00	$0.00	Disclosure SEC source: 0001209191-21-051674 · doc4.xml · derivative · entry 1 SCS Sponsor I LLC · CIK 0001850369 · Director · 10% owner Palihapitiya Chamath · CIK 0001715450 · Director · Chief Executive Officer · 10% owner Mehta Kishan · CIK 0001850520 · Director · President · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner ChaChaCha DNA I, LLC · CIK 0001869714 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,220,000 Underlying: Class A ordinary shares · 75,000 shares Expires not disclosed F1 · derivative.exercise_price: As described in the issuer's registration statement on Form S-1 (File No. 333-256723) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date. F2 · kind: On August 16, 2021, SCS Sponsor I LLC forfeited at no cost 75,000 shares of Class B ordinary shares of the issuer in connection with the election by the underwriters of the issuer's initial public offering to decline to exercise in full their option to purchase additional Class A ordinary shares. F1 · derivative.exercise_date: As described in the issuer's registration statement on Form S-1 (File No. 333-256723) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date. F1 · derivative.expiration_date: As described in the issuer's registration statement on Form S-1 (File No. 333-256723) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date. F3 · ownership.direct: The reporting owner, SCS Sponsor I LLC (the "Sponsor"), in whose name the securities reported herein are held, is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by ChaChaCha DNA I, LLC ("ChaChaCha"), which is controlled by Mr. Palihapitiya. Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Palihapitiya, Mehta and Cowen and ChaChaCha may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Each of Mr. Palihapitiya, Mr. Mehta, ChaChaCha and Mr. Cowen disclaims beneficial ownership of the shares held by the Sponsor, except to the extent of such person's pecuniary interest therein. Read SEC document
July 02, 2021 Filed Jul 7, 2021 20:47 UTC	Social Capital Suvretta Holdings Corp. II DNAB · Entity 125597	GrantClass A ordinary shares	640,000	$10.00	$6,400,000.00	Disclosure SEC source: 0001209191-21-045951 · doc4.xml · nonDerivative · entry 1 SCS Sponsor II LLC · CIK 0001850373 · Director · 10% owner Palihapitiya Chamath · CIK 0001715450 · Director · Chief Executive Officer · 10% owner Mehta Kishan · CIK 0001850520 · Director · President · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner ChaChaCha DNA II, LLC · CIK 0001869716 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 640,000 F1 · ownership.direct: The reporting owner, SCS Sponsor II LLC (the "Sponsor"), in whose name the securities reported herein are held, is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by ChaChaCha DNA II, LLC ("ChaChaCha"), which is controlled by Mr. Palihapitiya. Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Palihapitiya, Mehta and Cowen and ChaChaCha may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Each of Mr. Palihapitiya, Mr. Mehta, ChaChaCha and Mr. Cowen disclaims beneficial ownership of the shares held by the Sponsor, except to the extent of such person's pecuniary interest therein. Read SEC document
July 02, 2021 Filed Jul 7, 2021 20:52 UTC	PROKIDNEY CORP. DNAC · Entity 5181	GrantClass A ordinary shares	640,000	$10.00	$6,400,000.00	Disclosure SEC source: 0001209191-21-045953 · doc4.xml · nonDerivative · entry 1 SCS Sponsor III LLC · CIK 0001850379 · Director · 10% owner Palihapitiya Chamath · CIK 0001715450 · Director · Chief Executive Officer · 10% owner Mehta Kishan · CIK 0001850520 · Director · President · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner ChaChaCha DNA III, LLC · CIK 0001869713 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 640,000 F1 · ownership.direct: The reporting owner, SCS Sponsor III LLC (the "Sponsor"), in whose name the securities reported herein are held, is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by ChaChaCha DNA III, LLC ("ChaChaCha"), which is controlled by Mr. Palihapitiya. Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Palihapitiya, Mehta and Cowen and ChaChaCha may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Each of Mr. Palihapitiya, Mr. Mehta, ChaChaCha and Mr. Cowen disclaims beneficial ownership of the shares held by the Sponsor, except to the extent of such person's pecuniary interest therein. Read SEC document
July 02, 2021 Filed Jul 7, 2021 20:42 UTC	Akili, Inc. DNAA · Entity 89130	GrantClass A ordinary shares	640,000	$10.00	$6,400,000.00	Disclosure SEC source: 0001209191-21-045949 · doc4.xml · nonDerivative · entry 1 SCS Sponsor I LLC · CIK 0001850369 · Director · 10% owner Palihapitiya Chamath · CIK 0001715450 · Director · Chief Executive Officer · 10% owner Mehta Kishan · CIK 0001850520 · Director · President · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner ChaChaCha DNA I, LLC · CIK 0001869714 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 640,000 F1 · ownership.direct: The reporting owner, SCS Sponsor I LLC (the "Sponsor"), in whose name the securities reported herein are held, is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by ChaChaCha DNA I, LLC ("ChaChaCha"), which is controlled by Mr. Palihapitiya. Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Palihapitiya, Mehta and Cowen and ChaChaCha may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Each of Mr. Palihapitiya, Mr. Mehta, ChaChaCha and Mr. Cowen disclaims beneficial ownership of the shares held by the Sponsor, except to the extent of such person's pecuniary interest therein. Read SEC document
July 02, 2021 Filed Jul 7, 2021 20:56 UTC	Social Capital Suvretta Holdings Corp. IV DNAD · Entity 123913	GrantClass A ordinary shares	640,000	$10.00	$6,400,000.00	Disclosure SEC source: 0001209191-21-045954 · doc4.xml · nonDerivative · entry 1 SCS Sponsor IV LLC · CIK 0001850376 · Director · 10% owner Palihapitiya Chamath · CIK 0001715450 · Director · Chief Executive Officer · 10% owner Mehta Kishan · CIK 0001850520 · Director · President · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner ChaChaCha DNA IV, LLC · CIK 0001869773 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 640,000 F1 · ownership.direct: The reporting owner, SCS Sponsor IV LLC (the "Sponsor"), in whose name the securities reported herein are held, is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by ChaChaCha DNA IV, LLC ("ChaChaCha"), which is controlled by Mr. Palihapitiya. Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Palihapitiya, Mehta and Cowen and ChaChaCha may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Each of Mr. Palihapitiya, Mr. Mehta, ChaChaCha and Mr. Cowen disclaims beneficial ownership of the shares held by the Sponsor, except to the extent of such person's pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.